Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
DUBLIN - Goldman Sachs & Co. LLC disclosed on Monday its trading activity in Avadel Pharmaceuticals PLC (NASDAQ:AVDL) shares, reporting a long position of 1.18% and a short position of 0.57% following dealings on November 28, 2025.
According to a regulatory filing with the Irish Takeover Panel, Goldman Sachs held 1,081,414 ordinary shares representing 1.11% of Avadel, along with derivatives accounting for an additional 69,568 shares or 0.07%. The firm’s short position consisted of 493,055 shares (0.50%) and derivatives covering 63,843 shares (0.06%).
The disclosure detailed numerous purchase and sale transactions executed on November 28, with share prices ranging between $21.41 and $21.54. Notable transactions included a borrowing of 168,600 new shares and various returns of borrowed positions.
The filing identified Goldman Sachs as an advisor to Avadel Pharmaceuticals, which explains the required disclosure under Irish takeover regulations. The firm also reported open swap positions, including a sold position relating to 84 securities expiring December 17, 2025, and a purchased position relating to 33,762 securities expiring January 20, 2026.
The disclosure was made in compliance with Rule 38.5(b) of the Irish Takeover Panel Act, which requires reporting of dealings by connected exempt principal traders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.